Beam's BEAM-302 base editing therapy sustains AAT levels through one year in AATD as the pivotal Phase 1/2 cohort advances.
September 8, 2026 04:30 AM EDT
R&DCell/Gene Tx
Beam says AATD base editing data hold up after one year
Ayisha Sharma
News Reporter
Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin…
Prime Medicine wins arbitration vs Beam Therapeutics, plans FDA IND filing for genetic liver disease treatment. $PRME stock rises…
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed…
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African…
Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections,…
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on…
